The hallmark of chronic myelogenous leukemia is the transocation ofthe human c-abl protooncogene (ABL) from chromosome 9 to the specific breakpoint cluster region The t(9;22)(q34;qll) translocation is exceedingly consistent and is present in >95% of patients with chronic myelogenous leukemia (CML) (reviewed in ref.
p2lOac1R-L chimeric protein is composed of unique sequences of ABL amino acids joined to BCR amino acids that are expressed only by malgant cells. The current study demonstrates that the joining region of BCR-ABL protein is immunogenic to murine T cells. Immunization of mice with synthetic peptides corresponding to the joining region elicited peptidespecific, CD4+, class I major histocompatibility complexrestricted T cells. The BCR-ABL peptide-specific T cells recognized only the combined sequence of BCR-ABL amino acids and not BCR or ABL amino acid sequences alone. Importantly, the BCR-ABL peptide-specific T cells could recognize and proliferate in response to p2j(BCR-ABL protein.
The responsipptide-specific T cells to protein demonstrated that p210bc L can he processed by antigen-presenting cells so that the joining segment is bound to class II major histocompatibility complex molecules in a confignration similar to that of the uniin peptide and in a concentration hih efgto u-Mate the antigen-specific T-cell receptor. Thus, BCR-ABL pron ents a potential tumor-specific antigen related to the tnsfoming event and shared by many individuals with chronic myelogenous leukemia.
The t(9;22)(q34;qll) translocation is exceedingly consistent and is present in >95% of patients with chronic myelogenous leukemia (CML) of children and 25% of adults with ALL. In animal models, disseminated leukemia can be eradicated by the use of T cells immune to retrovirus-encoded leukemiaassociated antigens (14, 15) . A major obstacle preventing successful application of similar therapy to humans is a lack of well-characterized antigens that are both uniquely expressed on malignant cells and recognizable by T cells. Theoretically, any protein expressed by an altered cancerrelated gene, such as a protooncogene, is a potential T-cell target. This concept is just beginning to be evaluated (16) . In general, T cells do not recognize intact proteins but, rather, recognize short peptide fragments, 8-12 amino acids in length, that have been derived from intact protein processed intracellularly and presented in the cleft of major histocompatibility complex (MHC)-encoded molecules. Thus, the appropriateness of any particular protooncogene product to serve as a T-cell target will depend upon whether the altered segment of protein has the proper molecular configuration or " motif" to bind in the cleft of class I or class II MHC molecules; whether the resultant peptide/MHC molecule complex is present at the cell surface of the target cell or antigen-presenting cell (APC) in a concentration high enough to stimulate the specific T-cell receptor (17, 18) ; and, finally, whether the peptide/MHC molecule complex is within the T-cell receptor repertoire of the particular nominated individuals (17) (18) (19) (20) (21) with 2 mM EDTA, 100 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 50 jig ofleupeptin per ml, 100 units of aprotinin per ml, and 20 mM benzamidine (24) . The cells were homogenized by use of ultrasonic cell disrupter (model W-380, Heat Systems/Ultrasonics), the homogenate was centrifuged for 10 min at 3000 x g, and the supernatant was centrifuged at 100,000 x g for 90 min. The high molecular weight (Mr > 100,000) supernatant proteins in the cell extracts were isolated and concentrated by using a PM100 DiAFLO ultrafilter (Amicon). The partially purified BCR-ABL proteins were immunoprecipitated from the lysate with monoclonal antibody to BCR (Oncogene Science, Manhasset, NY), separated by SDS/PAGE, and identified by Western immunoblotting with antibody to ABL (Oncogene Science). The BCR-ABL proteins were aliquoted and stored at -70°C.
Immunization Protocols and Proliferation Assays. Mice were inoculated twice at 2-week intervals by subcutaneous injection with complete Freund's adjuvant (Sigma), alone or emulsified with BCR3-ABL2 peptide (100 ,ug). Ten days after the final immunization, single-cell suspensions of draining lymph nodes and spleens were prepared in medium consisting of a 1:1 mixture of RPMI 1640 medium (GIBCO) and EHAA medium (Biofluids, Rockville, MD) with 25 ,tM 2-mercaptoethanol, 200 units of penicillin per ml, 200 units of streptomycin per ml, 10 mM L-glutamine, and 10% fetal bovine serum. For proliferation assays, lymphocytes were cultured in 96-well plates at Generation and Characterization of p2lOBCRABLSpecific T-Cell Clones. Lymphocytes from the draining lymph nodes of mice immunized with BCR3-ABL2 peptide were cultured in 24-well culture plates at 4 x 106 cells per well with 2 x 106 irradiated syngeneic spleen cells and BCR3-ABL2 peptide at 25 ,ug/ml (total volume, 2 ml). The plates were cultured in a humidified atmosphere under 5% CO2 tension at 37°C for 5 days and then split 1:2. After 10 days, lymphocytes were restimulated at 1 x 106 lymphocytes per well in 24-well culture plates with 5 x 106 irradiated syngeneic spleen cells and peptide at 25 ,g/ml. Two days after the second in vitro stimulation, T cells were plated at 0.5 cell per well in 96-well flat-bottom plates with 1 x 106 irradiated syngeneic spleen cells and recombinant interleukin 2 (rIL-2) (at 50 units/ml). Derived T-cell clones were maintained by periodic stimulation with peptide (1 ,ug/ml) plus irradiated syngeneic spleen cells followed by expansion with rIL-2 (10 units/ml) every 2 weeks. T-cell clones were stained with fluorescein-conjugated anti-Thy-1.2 (1%), fluorescein-conjugated anti-Lyt-2 (2%), or phycoerythrin-conjugated anti-L3T4 (3%) monoclonal antibodies (Becton Dickinson) at 4°C for 45 min.
RESULTS
Synthetic Peptides Corresponding to the Joining Region of p210BCR-ABL Protein Can Elicit T-Cell Responses. BALB/c mice were immunized with a synthetic 12-amino acid peptide identical to the joining region of the p210 protein in K562 CML cells, termed BCR3-ABL2 peptide (Table 1) . Immunity was validated by the demonstration that host lymph node and splenic lymphocytes from immunized mice proliferated in vitro in response to the immunizing peptide but not control peptides (Fig. 1) . Similar data were generated in the B6 mouse strain. The immunizing peptide, GFKQSSKALQRP, contained six amino acids from BCR (GFKQSS), one fusion amino acid (K), and five amino acids from ABL (ALQRP) ( Table 1) . To examine for fine specificity, the T-cell lines were cloned by limiting dilution and maintained by episodic restimulation with the BCR3-ABL2 peptide. All clones were Thy-1.2+ CD4+ CD8-by analysis with fluoresceinated antibodies. Depending upon which BCR domains are included, the BCR-ABL chimeric protein takes two major forms in CML (BCR2-ABL2 and BCR3-ABL2) and one major form in ALL (BCRI-ABL2) (9-13). In each case, the ABL sequence of amino acids is identical but is joined with distinct BCR amino acid sequences. Data from nine representative clones (Table 2 ) demonstrated that the immune T cells responded specifically to BCR3-ABL2 but not to the alternative BCR-ABL joining regions of BCR2-ABL2 or BCRI-ABL2. The immune T cells likewise failed to respond to peptides identical to the isolated amino acid sequence of BCR3 alone. Thus, the immunogenic determinant was specifically associated with the 12 amino acid residues of the joining region of the p2lOBCR3-ABL2 protein.
The concentration of BCR3-ABL2 peptide necessary to induce proliferation varied. In general, optimal stimulation occurred in the range of 1-5 ,ug/ml, but some clones responded vigorously to as low as 0.04 ,ug/ml, the lowest concentration tested (Table 3) . Antigen-specific responses of CD4+ T cells require not only binding to class II MHC molecules on APCs but also display of the antigenic epitope in the proper orientation in the MHC cleft. The addition or alteration of flanking amino acids can alter binding, and T cells derived by immunizing with a particular peptide might respond only to that particular peptide. Thus, two BCR3-ABL2-specific T-cell clones derived by immunization with a 12-mer BCR3-ABL2 peptide were tested for response to 14-, 16-, 18-, and 22-mer peptides synthesized to be identical to the naturally occurring amino acid sequences of the p210 joining region. The 12-mer BCR3-ABL2 peptide-specific T cells responded to each of the longer peptides (Table 4) , (Table 5 ).
The proliferative response to p210BCR-ABL was less than the response to peptide, presumably due either to fewer joiningregion segments being present in the protein preparation on a per weight basis or to competition for binding to MHC molecules by alternative segments of the protein.
DISCUSSION
The results provide evidence that the generation of T-cell responses to BCR-ABL protein is possible. Immunity was directed specifically against the 12 amino acid residues of the joining region, validating that the p210BCR-ABL protein consisting of 1931 amino acid residues can be processed by APCs so that thejoining-region segment is bound in the cleft ofclass II MHC molecules in a concentration high enough to stimulate T cells, and in a configuration similar to the configuration engendered when mice were immunized with a 12-mer joining-segment peptide. The immunizing peptide was composed of six BCR, one fusion, and five ABL amino acids. The c-abl -+ bcr translocation is not known to occur in mice. However, expression of the human BCR-ABL gene in mice leads to a malignant syndrome similar to CML (25, 26) . The c-abl- encoded amino acids of the joining region are identical in mice and humans. It is unknown whether the bcr-encoded amino acids are expressed normally in mice. Thus, the bcr segment might be xenogeneic. However, the immune response generated was not to BCR residues alone. The novel antigenic determinant created by the chimeric protein required both BCR and ABL residues. In humans the BCR-ABL protein is expressed only by leukemic cells. Thus, the joining-region segment is unique to humans as well as mice and similar responses in humans are possible.
Studies by others have shown that analogous BCR-ABL joining-region peptides could elicit specific antibody responses to BCR-ABL proteins (27, 28) . Elicitation of an antibody response often requires a concurrent CD4' helper T-cell response. The current study provides direct evidence that a T-cell response to BCR-ABL joining-region peptides is possible. The importance of the observation that peptidespecific T cells can also respond to BCR-ABL protein is the speculation that BCR-ABL proteins may be appropriate targets for therapeutic T-cell attack. BCR-ABL proteins are appealing candidate targets for immunotherapy for several reasons. (i) BCR-ABL protein is an antigen shared by many individuals, being detected in >90% of patients with CML and 13% of patients with ALL (1). (ii) BCR-ABL protein is intimately associated with malignant transformation as well as maintenance of the malignant phenotype (27) (28) (29) (30) . CML is by all evidence a monoclonal expansion of a single aberrant pleuripotent stem cell (31) . Although controversial (31, 32) , it is likely that p210BCRBL protein is present in the earliest progenitor malignant cells. Only rarely does Ph'-positive CML become Ph1-negative, and only rarely does Ph1-positive CML lose detectable BCR-ABL transcripts during disease progression (33) . Thus, antigen-negative variants are not a perceived problem. (iii) T cells in CML are almost always Ph'-negative, at least in chronic phase, and thus, any autochthonous T-cell lines to be used for therapy would not be derived from the leukemic clone (34) . (iv) Antigenicity of BCR-ABL protein is presumably restricted to the joining region, which is expressed only by malignant cells or "premalignant" cells undergoing transformation. Therefore, therapy would be selective, minimizing the potential for autoimmune toxicity. (v) Normal bone marrow precursors commonly coexist with the malignant clone in the bone marrow of CML patients, so that selective destruction of the malignant clone could leave normal hematopoiesis intact.
Whether BCR-ABL protein expressed by CML cells is an appropriate target for T-cell therapy is an open experimental question. In animal models the adoptive transfer of immune tumor antigen-specific CD4' or CD8' T cells alone can mediate tumor therapy, but the combination is generally more effective (15) . Therapy mediated by immune CD4' T-cell responses in vivo requires that antigen be present in the environment of APCs in high enough concentrations to stimulate the immune T cells to proliferate and to secrete the cytokines involved in direct and/or indirect cytolytic mechanisms. BCR-ABL protein is normally found in the cytosol (35) and is not considered to be a secreted protein, but it might be found in the external cellular environment as a result of normal cell death and turnover or as a result of other therapeutic interventions such as cytolytic chemotherapy. We are not aware of any studies that have examined this issue, but our recent preliminary studies have shown that BCR-ABL protein can be detected in vitro in spent culture supernatants. Studies by others have validated that other protooncogene-encoded proteins known to exist normally and function intracellularly can be found in body fluids (36) and in the proximate tumor microenvironment (37) . Thus, BCR-ABL protein might be available in the external cell environment at sites of tumor to be processed and presented by autologous APCs expressing class II MHC molecules. The availability of BCR-ABL protein to T cells in vivo needs to be evaluated. Irrespective of the amount of BCR-ABL protein that is normally released by CML cells in vivo, the demonstration that intracellular protooncogene products are immunogenic and can potentially serve as tumor-specific antigens should focus experimental attention on learning how to target immunity to such antigens.
An alternative approach to focus immunotherapy against BCR-ABL protein would be to develop CD8' class I MHCrestricted cytolytic responses. The binding of peptides to class I MHC molecules occurs for protein synthesized by the target itself to the exclusion of proteins in the external environment (21) . The features associated with high-affinity binding of peptides to MHC molecules are just beginning to be elucidated. However, peptides that bind to class II MHC molecules often also bind to class I MHC molecules (38) .
Thus, CD8' class I MHC-restricted cytotoxic T-cell responses to the BCR-ABL joining region segment are conceivable.
The hallmark of malignant transformation is DNA alterations. The immune system normally subserves the function of discriminating self and non-self. Any protein expressed by altered DNA is potentially immunogenic. With knowledge of the DNA sequence of mutated or chimeric cancer-related genes, it should now be possible to derive the amino acid sequences of the aberrant expressed proteins and to determine whether the aberrant proteins are immunogenic to the autochthonous host. The current study confirms the hypothesis that BCR-ABL chimeric protein expressed by Ph1 in CML is immunogenic by virtue of the unique joining-region amino acid sequences. Although the current study focused on evaluation of immune responses to p210BCR-ABL protein in leukemic cells, it is anticipated that the methods can be extended to the evaluation of the immunogenicity of proteins expressed by other translocated genes commonly associated with leukemia and lymphoma or by somatically mutated cancer-related genes.
